Ignite Creation Date:
2025-12-25 @ 4:52 AM
Ignite Modification Date:
2026-03-05 @ 3:31 AM
Study NCT ID:
NCT03825718
Status:
COMPLETED
Last Update Posted:
2022-04-28
First Post:
2019-01-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Sponsor:
Hebei Yanda Ludaopei Hospital
Organization:
Study Overview
Official Title:
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is an early, open, single-centered trial.
Detailed Description:
The aim of this study is to evaluate the safety and tolerance of GC007F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 20 subjects to receive GC007F therapy.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: